News & Blog

Partnerships are Key to Driving Innovation and Value in Drug Development: A View from the Top

Endpoints News: Out to prove the next big I/O target, Immunitas’ chief dealmaker steps up to CEO role

Immunitas Therapeutics Names Amanda Wagner as CEO

Artificial Intelligence and Drug Discovery: Cutting Edge AI to Address Pediatric Diseases

Immunotherapy and Cancer: Cutting Edge Science to Address a Devastating Disease

Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer

2021 Year to Date Update

FinSMEs: Immunitas Therapeutics Closes $58M in Series B Financing

Endpoints: Touting CD161 as a test case for single-cell tech, Longwood-backed Immunitas bags $58M for next-gen I/O work

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases